Laboratory of Food Biotechnology, Institute of Food, Nutrition and Health,ETH Zurich, Schmelzbergstrasse 7,8092Zurich,Switzerland.
Laboratory of Human Nutrition, Institute of Food, Nutrition and Health,ETH Zurich, Schmelzbergstrasse 7,8092Zurich,Switzerland.
Br J Nutr. 2014 Aug 28;112(4):547-56. doi: 10.1017/S0007114514001160. Epub 2014 Jun 11.
Fe supplementation is a common strategy to correct Fe-deficiency anaemia in children; however, it may modify the gut microbiota and increase the risk for enteropathogenic infection. In the present study, we studied the impact of Fe supplementation on the abundance of dominant bacterial groups in the gut, faecal SCFA concentration and gut inflammation in children living in rural South Africa. In a randomised, placebo-controlled intervention trial of 38 weeks, 6- to 11-year-old children with Fe deficiency received orally either tablets containing 50 mg Fe as FeSO₄ (n 22) for 4 d/week or identical placebo (n 27). In addition, Fe-sufficient children (n 24) were included as a non-treated reference group. Faecal samples were analysed at baseline and at 2, 12 and 38 weeks to determine the effects of Fe supplementation on ten bacterial groups in the gut (quantitative PCR), faecal SCFA concentration (HPLC) and gut inflammation (faecal calprotectin concentration). At baseline, concentrations of bacterial groups in the gut, faecal SCFA and faecal calprotectin did not differ between Fe-deficient and Fe-sufficient children. Fe supplementation significantly improved Fe status in Fe-deficient children and did not significantly increase faecal calprotectin concentration. Moreover, no significant effect of Fe treatment or time × treatment interaction on the concentrations of bacterial groups in the gut or faecal SCFA was observed compared with the placebo treatment. Also, there were no significant differences observed in the concentrations of any of the bacterial target groups or faecal SCFA at 2, 12 or 38 weeks between the three groups of children when correcting for baseline values. The present study suggests that in African children with a low enteropathogen burden, Fe status and dietary Fe supplementation did not significantly affect the dominant bacterial groups in the gut, faecal SCFA concentration or gut inflammation.
铁补充是纠正儿童缺铁性贫血的常用策略；然而，它可能会改变肠道微生物群，并增加肠道致病性感染的风险。本研究旨在研究铁补充对南非农村地区儿童肠道中优势细菌群丰度、粪便短链脂肪酸浓度和肠道炎症的影响。在一项为期 38 周的随机、安慰剂对照干预试验中，6-11 岁缺铁的儿童每周口服 4 天 50mgFe 的硫酸亚铁片剂（n=22）或相同的安慰剂（n=27）。此外，还纳入了铁充足的儿童（n=24）作为非治疗参考组。在基线和第 2、12 和 38 周时分析粪便样本，以确定铁补充对肠道中 10 种细菌群（定量 PCR）、粪便短链脂肪酸浓度（HPLC）和肠道炎症（粪便钙卫蛋白浓度）的影响。在基线时，缺铁和铁充足儿童的肠道细菌群、粪便短链脂肪酸和粪便钙卫蛋白浓度没有差异。铁补充显著改善了缺铁儿童的铁状态，且粪便钙卫蛋白浓度没有显著增加。此外，与安慰剂治疗相比，铁治疗或时间×治疗相互作用对肠道细菌群或粪便短链脂肪酸浓度没有显著影响。此外，当校正基线值时，三组儿童在第 2、12 或 38 周时，任何细菌靶群或粪便短链脂肪酸的浓度均无显著差异。本研究表明，在肠道病原体负担较低的非洲儿童中，铁状态和膳食铁补充对肠道中优势细菌群丰度、粪便短链脂肪酸浓度或肠道炎症没有显著影响。
